Group 1 - The stock price of Zhaoxin Biopharmaceuticals (02509.HK) has shown volatility over the past week, with an overall downward trend, closing at HKD 19.33 on February 13, 2026, down 2.37% for the day [1] - The stock experienced a trading range of 10.03% over the past five days, with a total trading volume of approximately HKD 16.88 million, indicating increased market activity [1] - Technical indicators suggest short-term price pressure, with the MACD histogram remaining negative and the KDJ J-line dropping to 7.39 [1] Group 2 - Matrix Life Vision's report on February 12, 2026, highlights Zhaoxin Biopharmaceuticals as a biotech company focused on autoimmune and allergic diseases, with key products like QX005N (IL-4Rα monoclonal antibody) and QX002N (IL-17A monoclonal antibody) in late-stage clinical trials [2] - The report notes that while the company faces intense competition and clinical failure risks, its long-term growth potential hinges on the commercialization progress of its core products [2] - In the first half of 2025, the company reported a significant revenue increase of 359.69% to HKD 206 million, with losses narrowing by 83.11%, indicating a strong cash flow situation to support R&D [2]

荃信生物-B(02509)公布，2026年2月6日耗资约32.6万港元回购1.62万股股份。 ...

Group 1 - The company, Qianxin Biotech-B (02509.HK), announced a share buyback on February 6, 2023, spending HKD 326,000 to repurchase 16,200 shares [1]

Group 1 - The company, Zhenxin Biotechnology-B (02509), announced a share buyback on February 6, 2026, costing approximately HKD 326,000 for 16,200 shares [1]

公司名稱： 江蘇荃信生物醫藥股份有限公司 呈交日期： 2026年2月6日 FF305 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2026年2月4日 | 224,583,800 | | 2,487,800 | | 227,071,600 | | 1). 購回股份 (股份被持作庫存股份) | | -16,200 | 0.0072 % | 16,200 HKD | 20.1232 | | ...

Core Viewpoint - The company believes its current stock price is significantly undervalued and aims to enhance market confidence and investment value through share buybacks [1] Group 1: Share Buyback Details - The company has repurchased a total of 2.4878 million ordinary shares as treasury stock from November 6, 2025, to the date of the announcement [1] - The repurchased shares represent approximately 1.10% of the company's existing issued share capital as of the announcement date [1] - The total amount involved in the buyback is approximately HKD 50.75 million, excluding commissions and other expenses [1]

Core Viewpoint - The company believes its current stock price is significantly undervalued and aims to enhance market confidence and investment value through share buybacks [1] Group 1: Share Buyback Details - The company has repurchased a total of 2.4878 million ordinary shares as treasury stock from November 6, 2025, to the date of the announcement [1] - The repurchased shares represent approximately 1.10% of the company's existing issued share capital as of the announcement date [1] - The total amount involved in the buyback is approximately HKD 50.75 million, excluding commissions and other expenses [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本 公 告 乃 由 江 蘇 荃 信 生 物 醫 藥 股 份 有 限 公 司（「本公司」）自 願 刊 發，以 向 股 東 及 潛 在投資者提供本公司最新的業務發展狀況。 本 公 司 董 事 會（「董事會」）認 為 本 公 司 目 前 股 價 嚴重低估 本 公 司 的 價 值。憑 藉 對 本 公 司 未 來 發 展 前 景 的 充 分 信 心 及 對 本 公 司 內 在 價 值 的 高 度 認 同，為 持 續 增 強 市 場 對本公司的信心並提升本公司的投資價值，根據本公司股東於2025年6月20日舉行 的股東週年大會上 批 准 授 予 本 公 司 董 事（「董 事」）的股份購回授權，本公司已於2025 年11月6日至本公告日期在香港聯合交易所有限公司購回合共2,487,800股普通股作 為庫存股。所購回的股份佔本公司於本公告日期的現有已發行股份總 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江蘇荃信生物醫藥股份有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02509 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 227,071,600 | RMB | | 1 | RMB | | 227,071,600 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 227,071,600 | RMB | | 1 | RMB | | 227,071,600 | 本月底法定/註冊股本總額： RM ...

Group 1 - The company, Qianxin Biotech-B (02509.HK), announced a share buyback on February 4, spending HKD 1.871 million to repurchase 93,000 shares [1]